| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/13/2005 | WO2004103361A3 A pharmaceutical dosage form of citalopram |
| 01/13/2005 | WO2004100940B1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression |
| 01/13/2005 | WO2004099134A3 Glutaminyl based dp iv-inhibitors |
| 01/13/2005 | WO2004098567A3 Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
| 01/13/2005 | WO2004096197A3 5-aza-7-deazapurine nucleosides for treating flaviviridae |
| 01/13/2005 | WO2004091633A8 Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
| 01/13/2005 | WO2004089379A3 Pharmaceutical combination containing tamsulosin and a non-steroidal anti-inflammatory drug |
| 01/13/2005 | WO2004087880A8 Compounds and their use to treat diabetes and related disorders |
| 01/13/2005 | WO2004087097A3 Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer |
| 01/13/2005 | WO2004078744A3 Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain |
| 01/13/2005 | WO2004077062A3 Method for selecting a candidate drug compound |
| 01/13/2005 | WO2004076406A3 Losartan potassium polymorphs and process for the preparation thereof |
| 01/13/2005 | WO2004073654A3 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid |
| 01/13/2005 | WO2004073638A3 Method of lowering body temperature with (s)-2,3-benzodiazepines |
| 01/13/2005 | WO2004072047A8 Indoles, benzimidazoles or naphhimidazoles as histone deacetylase (hdac) inhibitors |
| 01/13/2005 | WO2004069195A3 Methods and compositions for treating inflammatory disorders of the airways |
| 01/13/2005 | WO2004064764A3 Substituted alkyl amido piperidines |
| 01/13/2005 | WO2004050035A3 Benzimidazoles and analogs thereof as antivirals |
| 01/13/2005 | WO2004048930A3 METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE ß-ADRENERGIC PATHWAY |
| 01/13/2005 | WO2004047833A3 Anthranilic acid amides and the derivatives thereof as cosmetic and pharmaceutical agents |
| 01/13/2005 | WO2004027381A3 Methods and compositions related to inhibiting nuclear envelope breakdown |
| 01/13/2005 | WO2003096983A3 Method of treating dyslipidemic disorders |
| 01/13/2005 | WO2003086408A8 Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases |
| 01/13/2005 | WO2003084922A8 Acyl-4-carboxyphenylurea derivatives, method for production and use thereof |
| 01/13/2005 | WO2003074073A3 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof |
| 01/13/2005 | WO2003070156A3 Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
| 01/13/2005 | US20050010196 Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
| 01/13/2005 | US20050010193 Novel methods for administration of drugs and devices useful thereof |
| 01/13/2005 | US20050010052 P2X7 receptor (a ligand-gated ion channel) antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases; osteoarthritis |
| 01/13/2005 | US20050010051 catalytically hydrogenating 4-[1-hydroxy-1-(2,3-dimethoxyphenyl)methyl]pyridine to provide 4-[1-hydroxy-1-(2,3-dimethoxyphenyl)methyl]piperidine, which is reacted with 4-fluorophenylacetylating reagent in the presence of base/solvent |
| 01/13/2005 | US20050010050 Antiinflammatory agents; antiarthritic agents; anticancer agents; analgesics |
| 01/13/2005 | US20050010048 Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors |
| 01/13/2005 | US20050010047 Angiogenesis inhibitors; psoriasis; rheumatic disorders; chronic obstructive pulmonary disease |
| 01/13/2005 | US20050010046 Topoisomerase poison agents |
| 01/13/2005 | US20050010042 Expression vector comprising nucleotide sequences comprising pro-polypeptide for use in the diagnosis, prevention and treatment of cell proliferative, inflammatory, cardiovascuar and nervous system disorders |
| 01/13/2005 | US20050010040 Generating proanthocyanidins from crude plant extracts; for use in treating inflammation and gastrointestinal disorders; for use as meat additives to inhibit food-borne pathogens |
| 01/13/2005 | US20050009930 Carotenoid analogs or derivatives for controlling connexin 43 expression |
| 01/13/2005 | US20050009929 Using terpene compound |
| 01/13/2005 | US20050009927 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors |
| 01/13/2005 | US20050009925 Administering atomoxetine or its hydrochloride or a 3-(o-alkylthiophenoxy)-3-phenyl-N-alkylpropylamine for the treatment of cognitive failure, including that due to dementia, delirium and schizophrenia |
| 01/13/2005 | US20050009923 Bronchodilating beta-agonist compositions and methods |
| 01/13/2005 | US20050009920 Taxol enhancer compounds |
| 01/13/2005 | US20050009919 Treating cachexia and excessive catabolism with (-)-hydroxycitric acid |
| 01/13/2005 | US20050009918 Penetration enhancer; polysaccharide gum or polyacrylic acid thickener; aliphatic alcohol or ester or liquid polyol; water; and a buffer; relieves constriction of a blood vessel in vasospasm and restores blood flow; improving microcirculation in a replanted body part. |
| 01/13/2005 | US20050009917 Prostaglandin, e.g., 1R,2R,3R,5R)-5-halo-2-[(1E,3S)-3-cycloalkyl-3-hydroxy-1-propenyl]-3-hydroxycyclopentyl]-(5Z)-5-alkenoic acids; treating in particular, symptoms of atopic dermatitis |
| 01/13/2005 | US20050009916 E.g., dextromethorphan hydrobromide, amantadine, memantine, remacemide or riluzole; treating pain resulting from injury, trauma, lesion or other disorders in the spinal cord or brain |
| 01/13/2005 | US20050009915 Method for preventing and/or treating perinatal asphyxia in a human or animal neonate |
| 01/13/2005 | US20050009914 Increasing the production of the blood-forming hormone erythropoietin, especially for the treatment of aging- or disease-related conditions associated with decreased oxygen supply to the tissue, especially in elderly subjects, in the treatment of malignant diseases and in cardiorespiratory disorders |
| 01/13/2005 | US20050009912 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives; treatment of neurological or psychiatric disorders, such as anxiety disorder; greatly enhanced oral exposure |
| 01/13/2005 | US20050009910 Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
| 01/13/2005 | US20050009905 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 01/13/2005 | US20050009904 Administering ascorbic acid, or salt thereof, in mixture with carnitine compound |
| 01/13/2005 | US20050009902 Treating any types of pruritus such as ocular pruritus, skin pruritus and systemic pruritus with a cannabinoid agonist such as palmidrol and anandamide or a derivative |
| 01/13/2005 | US20050009899 E.g., combination of cariporide and ramipril for preventing heart failure and other age-related organ dysfunctions, age-related disorders and for prolonging life |
| 01/13/2005 | US20050009898 New substituted indolinones, their manufacture and their use as medicaments |
| 01/13/2005 | US20050009897 Method of treatment |
| 01/13/2005 | US20050009896 Drugs comprising combination of antithrombotic agent with pyrazolone derivative |
| 01/13/2005 | US20050009895 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
| 01/13/2005 | US20050009894 Benzimidazole derivatives and their use as KDR kinase protein inhibitors |
| 01/13/2005 | US20050009893 Administering a renin-angiotensin system inhibitor, particularly an angiotensin-receptor-blocker, an ACE-inhibitor, or a vasopeptidase inhibitor, especially incombination with a hypotensive agent |
| 01/13/2005 | US20050009892 Phenyloxazole derivatives lower blood triglyceride, glucose, insulin; hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity; 2-methyl-2-[6-(5-methyl-2-phenyloxazol-4-yl)-(E)-4-hexenyloxy]propionic acid |
| 01/13/2005 | US20050009891 Synergistic combination of a thiazolecarboxamide derivative, especially N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, and an antiproliferative cytotoxic agent such as paclitaxel, procarbazine, mitoxantrone or an epidophyllotoxin |
| 01/13/2005 | US20050009888 Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release |
| 01/13/2005 | US20050009887 Method of resolving amlodipine racemate |
| 01/13/2005 | US20050009885 Administering the dihydropyridine calcium channel antagonist, nilvadipine to treat a cerebral amyloidogenic disease, such as Alzheimer's disease, transmissible spongiform encephalopathy, scrapie, traumatic brain injury, cerebral amyloid angiopathy and Gerstmann-Straussler-Scheinker syndrome |
| 01/13/2005 | US20050009884 Administering memantine to prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy |
| 01/13/2005 | US20050009878 4-(1,2-Dimethyl-1H-imidazol-4-ylethynyl)-2-methyl-pyridine compounds; treating chronic neurological disorders |
| 01/13/2005 | US20050009877 Methods of identifying HCV NS5B polymerase inhibitors and their uses |
| 01/13/2005 | US20050009876 Indazole compounds, compositions thereof and methods of treatment therewith |
| 01/13/2005 | US20050009875 Antiinflammatory agents |
| 01/13/2005 | US20050009874 Tetrahydropyridin or piperidino heterocyclic derivatives |
| 01/13/2005 | US20050009873 1-Acyl-2,4-dicarbonyldihydropyrrole derivatives, e.g., rel-(2S,5R)-1-(4-tert-butylbenzoyl)-2-isobutyl-5-(1,3-thiazol-2-yl)-2,5-dihydro-1H-pyyrole-2,4-dicarboxylic acid; properation by acylating the corresponding dihydropyrrole derivative |
| 01/13/2005 | US20050009872 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
| 01/13/2005 | US20050009870 3-(amino)sulfonylamino-substituted, e.g., N-(1,6-Dibenzyl-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide and N-(1-Benzyl-2-oxo-6-(thiophen-3-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide; eating, metabolic, obesity, cognitive, neurological, pain, inflammatory and psychiatric disorders |
| 01/13/2005 | US20050009868 Mixture of one or more RAR pan-antagonist compounds each of which has a high binding affinity to RAR alpha , RAR beta and RAR gamma; is administered to a population of cells to inhibit RAR mediated signalling and/or enhance RAR mediated repression leading to increased chondrogenesis. |
| 01/13/2005 | US20050009867 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 01/13/2005 | US20050009866 Treatment of cardiovascular disease with quinolinone enantiomers |
| 01/13/2005 | US20050009865 Quinoline derivative as diagnostic probe for disease with tau protein accumulation |
| 01/13/2005 | US20050009863 Used for treating renal disorders such as acute or chronic renal failure, biliary function disorders, respiratory disorders such as snoring or sleep apneas and strokes. |
| 01/13/2005 | US20050009862 Method for promoting uninterrupted sleep by administration of trospium chloride |
| 01/13/2005 | US20050009861 Inverse agonist has a functional efficacy at the alpha 1 and/or alpha 5 receptor subtypes of less than -5%, and the efficacy measured at the alpha 2 and alpha 3 receptor subtypes is greater than 5%, and is preferably a 4-oxo-1,4-tetrahydro-1,5- naphthyridine-3-carboxamide derivative |
| 01/13/2005 | US20050009859 Including multiple sclerosis, atheroslerosis, inflammatory bowel disease, Alzheimer's disease, stroke and diabetes by administering, e.g., 5-pyridin-2-yl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline, |
| 01/13/2005 | US20050009858 Imiquimod therapies |
| 01/13/2005 | US20050009857 Powder formulations containing tiotropium suitable for inhalation |
| 01/13/2005 | US20050009856 Administering a compound which inhibits selectively mu opioid receptor activity or activation to treat conditions including Huntington's disease, idiopathic torsion dystonia, tardive dyskinesia or off-dystonia in Parkinson's disease, and dyskinesias arising as a side-effect of a therapeutic agent. |
| 01/13/2005 | US20050009852 human orexin receptor antagonists; analgesics, antidiabetic agents; sleep apnea, insomnia |
| 01/13/2005 | US20050009851 Use of cyclopeta[g]quinazoline derivatives for treating cancer |
| 01/13/2005 | US20050009848 Use of antivirals against inflammatory bowel diseases |
| 01/13/2005 | US20050009847 Compounds and methods for increasing neurogenesis |
| 01/13/2005 | US20050009846 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders |
| 01/13/2005 | US20050009845 Thienopyrimidine compounds as protein tyrosine kinase inhibitors |
| 01/13/2005 | US20050009843 Thiazole derivatives of pyrido-1,2-a-pyrimidines, quinolones, pyridopyridazinoness, cinnolinones and naphthyridones; identifying a drug efflux pump expressed in a microorganism |
| 01/13/2005 | US20050009842 2-hydroxymethylcyclopropylidene methylpurines and -pyrimidines as antiviral agents |
| 01/13/2005 | US20050009840 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer |
| 01/13/2005 | US20050009839 Novel azoles having an insecticidal action |
| 01/13/2005 | US20050009838 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 01/13/2005 | US20050009837 Modulators of lipid metabolism and methods of use |
| 01/13/2005 | US20050009836 Ophthalmic composition containing quinolones and method of use |
| 01/13/2005 | US20050009835 Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors |
| 01/13/2005 | US20050009833 such as N-(4,5-Dibromo-3-methylthiophen-2-ylmethyl)-N'-(1H-quinolin-4-one)propane-1,3-diamine; methionyl t-RNA synthetase inhibitors |